Effect of valsartan versus lisinopril on peritoneal sclerosis in rats

International Journal of Artificial Organs

Volumn 28, Issue 2, 2005, Pages 156-163

  Duman, Soner ^a   Sen, S ^a   Duman, C ^b   Oreopoulos, D G ^c  

^a EGE UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Lisinopril; Peritoneal sclerosis; RAS; TGF 1; Valsartan; VEGF

Indexed keywords

EFFLUENTS; GLUCOSE; METABOLISM; POTABLE WATER; UREA;

ACE INHIBITORS; DIALYSATES; LISINOPRIL; PERITONEAL DIALYSIS; PERITONEAL SCLEROSE; RAS; TGF Β1; TGF-Β; VALSARTAN; VEGF;

RATS;

ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DIANEAL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; GLUCOSE; HYPERTONIC SOLUTION; LISINOPRIL; RILACE; TRANSFORMING GROWTH FACTOR BETA1; UREA; VALSARTAN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DIALYSATE; DRUG MECHANISM; EFFLUENT; EXPOSURE; GLUCOSE ABSORPTION; MALE; MEMBRANE TRANSPORT; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PROTECTION; RAT; SCLEROSIS; STATISTICAL ANALYSIS; THICKNESS; ULTRAFILTRATION; UREA BLOOD LEVEL; UREMIA; VOLUMETRY;

EID: 16844386539     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800212     Document Type: Article

References (45)

1. Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int 1999; 19: (suppl 3): S35-42.
2. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, Grabensee B. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int 2001; 78 (suppl): S42-7.
3. Selgas R, Fernandez-Reyes M-J, Bosque E, Bajo M-A, Borrego F, Jimenez C, et al. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective median long-term study. Am J Kidney Dis 1994; 23: 64-73.
4. Heimbürger O, Waniewski J, Werynski A, Tranæus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506.
5. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20: (suppl 3): S5-96.
6. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-9.
7. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 1716.
8. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102.
9. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33: 105-10.
10. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-9.
11. Chaimovitz C. Peritoneal dialysis. Kidney Int 1994; 45: 1226-40.
12. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
13. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001; 10: 321-9.
14. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-75.
15. Strutz F, Muller GA. Transdifferentiation comes of age. Nephrol Dial Transplant 2000; 15: 1729-31.
16. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993, 3: 1531-40.
17. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001, 38: 635-8.
18. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patient with diabetic nephropathy. Kidney Int 2000; 57: 601-6.
19. Border WA, Noble NA. TGF β in kidney fibrosis: A target for gene therapy. Kidney Int 1997; 51: 1388-96.
20. Peters H, Border WA, Noble NA. Targeting TGF β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54:1570-80.
21. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blonco J, Mezzano S, Egido J. ANG II also regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; 62: (suppl 82): S12-22.
22. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B, Marti HP. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003; 14: 2861-72.
23. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO. Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 2003; 23: 429-37.
24. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003; 163: 1261-73.
25. Thomas DW, Hoffman MD. Identification of macrophage receptor for angiotensin: A potential role in antigen uptake for T lymphocyte responses? J Immunol 1984; 132: 2807-12.
26. Fujiyama S, Matsubara H, Nozawa Y, et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88: 22-9.
27. Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003; 14: 3061-71.
28. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46: 5005-10.
29. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, Akcicek F, Atabay G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21: 219-24.
30. Şen S, Duman S, Basci A, Akçiçek F, Atabay G. Parietal peritoneal morphology with different fixatives in experimental studies (Abstract). Perit Dial Int 2002; 22: 152.
31. Duman S, Şen S, Günal AI, Akçiçek F, Başçi A. How can we standartize peritoneal thickness measurement in experimental studies in rats? Perit Dial Int 2001; 21: (suppl 3): S338-41.
32. Garosi G, Di Paolo N. Morphological aspects of peritoneal sclerosis. J Nephrol 2001; 14 (suppl 4): S30-8.
33. Hung KY, Tsai TJ, Chen WY. Peritoneal fibrosis and its prevention. Nephrology 2002; 7: 227-32.
34. Al-Jayyousi RH, Medcalf JM, Harris K PG. Role of transforming growth factor beta in peritoneal fibrosis. Nephrology 2002; 7: 227-32.
35. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19: 180-5.
36. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, Westenfeld R, Floege J, Rippe B. Biocompatibility of peritoneal dialysis fluids: Long-term exposure of nonuremic rats. Perit Dial Int 2004; 24: 37-47.
37. Agraharkar M, Du Y, Man-Wan C, Henry S, Kuo YF, Ahuja T. Angiotensin II receptor blockade (ARB) and peritoneal protein loss in peritoneal dialysis patients (Abstract). J Am Soc Nephrol 2003; 14: p. 858.
38. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patient with diabetic nephropathy. Kidney Int 2000; 57: 601-6.
39. Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, et al. A randomized, double blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20: 443-57.
40. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998; 352: 1252-6.
41. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
42. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 15: 139: 105-12.
43. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of angiotensin II receptor blocker, valsartan, on residual renal function on CAPD. Am J Kidney Dis 2004; 43: 1056-64.
44. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7.
45. Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 2004; 20: 31-6.